BioNTech SE (F:22UAy) (NASDAQ:BNTX) has been downgraded to “market perform” from “outperform” by Leerink Partners after a strong share price rally brought the stock closer to its near-term fundamental value. Leerink set a price target of $113 in a note published Monday, a move that sent BioNTech shares down more than 2%.
The downgrade follows a 24% rebound in BioNTech’s share price to around $113 from December lows near $92, significantly outperforming the roughly 4% gain recorded by the S&P Biotechnology Select Industry Index over the same period. Leerink said the rally has effectively closed the valuation gap based on its discounted cash flow analysis, limiting further upside at current levels.
“We are downgrading BioNTech (BNTX) to Market Perform (MP) following a successful 24% rally,” the analysts said, noting that the shares are now trading close to their revised $113 price target.
While maintaining a constructive long-term view on BioNTech’s oncology strategy, Leerink highlighted pumitamig — a VEGFA/PD-L1 bispecific antibody partnered with Bristol Myers Squibb — as a key asset. However, the firm said it does not expect clinical data capable of validating the value of those combinations before 2027 or later.
In the shorter term, Leerink expects BioNTech’s shares to remain volatile and move largely in response to data releases from competitors in the VEGFA/PD-(L)1 space. The analysts characterized those upcoming readouts as likely to be “negative to neutral,” a backdrop they said supports a more cautious outlook over the next 12 to 18 months.
The brokerage also flagged reduced upside from BioNTech’s cancer vaccine pipeline. Leerink noted that the company’s personalized cancer vaccine, autogene cevumeran, crossed a pre-specified futility boundary in a Phase 2 study in adjuvant colorectal cancer, lowering the chances of a positive surprise from that program.
Although Leerink pointed to gotistobart, BioNTech’s next-generation CTLA-4 antagonist, as a potential area of promise, it said the asset alone is unlikely to drive sustained share price gains. Data from the Phase 3 PRESERVE-003 study are expected in mid-2026, but the analysts described the outlook as “too narrow for this one win to meaningfully sustain stock appreciation.”
Leerink also highlighted BioNTech’s strong cash position, which stood at $20.3 billion (€17.2 billion), while noting that this balance is expected to decline as the company continues to invest aggressively in its oncology pipeline.
“We prefer to move to the sidelines until more meaningful clinical readouts begin in 2027,” the analysts wrote.
At the time of the report, BioNTech shares were trading at $113.75, close to their 52-week high of $124.98. The company does not pay a dividend and carries no net debt, according to Leerink.